Drug Trial Radar · NCT02571777
Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma
Last checked: Nov 19, 2026Latest source record: Jul 22, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,092
Actual
Start
Dec 8, 2015
Primary completion
Jun 14, 2019
Study completion Jun 14, 2019
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Oct 8, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the trial was to evaluate the efficacy and safety of two different doses of QVM149 (QVM149 150/50/80 μg and QVM149 150/50/160 μg via Concept1) over two respective QMF149 doses (QMF149 150/160 μg and QMF149 150/320) μg via Concept1 in poorly controlled asthmatics as determined by pulmonary function testing and effects on asthma control.
Conditions
- Asthma
Interventions
QVM149 150/50/160Drug
QVM149 150/50/80Drug
QMF149 150/320Drug
QMF149 150/160Drug
salmeterol/fluticasoneDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Trough Forced Expiratory Volume in 1 Second (Trough FEV1) of QVM149 Versus QMF149 at Week 26Time frame: 26 weeks
Locations
403 sites in 41 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Buenos Aires, Argentina
Novartis Investigative Site
Buenos Aires, Argentina
Novartis Investigative Site
Buenos Aires, Argentina
Novartis Investigative Site
Buenos Aires, Argentina
Novartis Investigative Site
Córdoba, Argentina
Novartis Investigative Site
Córdoba, Argentina
Novartis Investigative Site
Mendoza, Argentina
Novartis Investigative Site
Mendoza, Argentina
Novartis Investigative Site
Paraná, Argentina
Novartis Investigative Site
Santa Fe, Argentina
Novartis Investigative Site
Santa Fe, Argentina
Novartis Investigative Site
Bahía Blanca, Buenos Aires, Argentina
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Novartis Investigative Site
Florida, Buenos Aires, Argentina
Novartis Investigative Site
Lanus, Buenos Aires, Argentina
Novartis Investigative Site
Mar del Plata, Buenos Aires, Argentina
Novartis Investigative Site
Mar del Plata, Buenos Aires, Argentina
Novartis Investigative Site
Nueve de Julio, Buenos Aires, Argentina
Novartis Investigative Site
San Nicolás de los Arroyos, Buenos Aires, Argentina
Novartis Investigative Site
Vicente López, Buenos Aires, Argentina
Novartis Investigative Site
Villa María, Córdoba Province, Argentina
Novartis Investigative Site
Concepción del Uruguay, Entre Ríos Province, Argentina
Novartis Investigative Site
Godoy Cruz, Mendoza Province, Argentina
Novartis Investigative Site
Santa Fe, Rosario, Argentina
Novartis Investigative Site
Rosario, Santa Fe Province, Argentina
Novartis Investigative Site
Rosario, Santa Fe Province, Argentina
Novartis Investigative Site
Rosario, Santa Fe Province, Argentina
Novartis Investigative Site
Rosario, Santa Fe Province, Argentina
Novartis Investigative Site
Rosario, Santa Fe Province, Argentina
Novartis Investigative Site
Rosario, Santa Fe Province, Argentina
Novartis Investigative Site
San Miguel de Tucumán, Tucumán Province, Argentina
Novartis Investigative Site
Bludenz, Austria
Novartis Investigative Site
Feldbach, Austria
Novartis Investigative Site
Feldkirch, Austria
Novartis Investigative Site
Grieskirchen, Austria
Novartis Investigative Site
Braine L Alleud Waterloo, Belgium
Novartis Investigative Site
Brussels, Belgium
Novartis Investigative Site
Brussels, Belgium
Novartis Investigative Site
Éghezée, Belgium
Showing 40 of 403 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.